The University of Chicago Header Logo

Connection

Walter M. Stadler to Receptor, Fibroblast Growth Factor, Type 3

This is a "connection" page, showing publications Walter M. Stadler has written about Receptor, Fibroblast Growth Factor, Type 3.
  1. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.
    View in: PubMed
    Score: 0.127
  2. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.